Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Our mission is to develop unique and innovative therapeutics based on our unique understanding of galectin proteins. We strive to improve the lives of patients by developing products that improve their quality of life.

Our vision is to become a leader in the development of galectin-based therapeutics for the treatment of cancer, fibrotic diseases, and other disorders.

Galectin Therapeutics has earned numerous awards in the area of biotechnology and drug development, including being named a Technology Pioneers 2013 by the World Economic Forum, winning the Red Herring Europe Top 100 Award in 2015, and receiving the Frost & Sullivan Technology and Innovation Award in 2016.